At least 12 generic drug makers were poised to divvy up the $1.8-billion pie of metformin, the generic equivalent of Bristol-Myers Squibb's type 2 diabetes drug Glucophage, as of Feb. 4.
Alpharma, Barr Laboratories, Eon Labs, Genpharm, Ivax, Mylan Laboratories, Pharmaceutical Resources, Teva Pharmaceuticals and several others are among the generic drug makers who will begin launching generic Glucophage.
BMS, which had held on tenaciously to the Glucophage patent, recently exhausted its last legal option.
The bevvy of virtually simultaneous metformin approvals may cause a generic price war. Responding to a Drug Store News inquiry, the FDA confirmed that, while several metformin approvals were issued on the same day, no generic drug maker received the lucrative 180-day period of sales exclusivity.
COPYRIGHT 2002 Reproduced with permission of the copyright holder. Further reproduction or distribution is prohibited without permission.
COPYRIGHT 2002 Gale Group
Contact
Home
A
Gabapentin